3 results
To investigate whether a treatment strategy offering bezlotoxumab before FMT in patients suffering from multiple recurrent CDI results in equal efficacy compared with a treatment strategy with initial FMT. Strategy A includes bezlotoxumab as…
Primary objectives:Phase 1b:Arm A (BGB-290 + radiation therapy [RT]): Subjects with first-line glioblastoma (GB) with unmethylated MGMT promoter (*unmethylated GB*)• To assess safety and tolerability of BGB-290 combined with RT• To identify dose-…
Since previous findings underline the hypothesis that ER may play a key role as an underlying mechanism leading to (re)victimisation, we suggest that a clinical intervention aimed at enhancing ER skills may decrease (re)victimisation risk. Therefore…